This report is an independent analysis of the adoption of Good Regulatory Practices (GRP) in pharmaceutical product regulation in eight (8) Latin American countries.
The information comes from reliable sources; however, the data and information described herein will be subject to updates and validation. This study is not an evaluation of the maturity level of national drug regulatory authorities, nor does it substitute or replace official assessments conducted by authorized bodies such as the World Health Organization (WHO) or the Pan American Health Organization (PAHO).